<DOC>
	<DOCNO>NCT00078793</DOCNO>
	<brief_summary>This study evaluate long-term safety etanercept without DMARDs child polyarticular course systemic juvenile rheumatoid arthritis ( JRA ) compare cohort subject polyarticular systemic JRA receive methotrexate without DMARDs .</brief_summary>
	<brief_title>Registry Etanercept ( EnbrelÂ® ) In Children With Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>JRA American College Rheumatology ( ACR ) criterion Active joint Initiate etanercept alone , etanercept plus methotrexate DMARDs , methotrexate alone , methotrexate DMARDs within 6 month entry Registry Polyarticular systemic RA 3 joint start treatment</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>JRA</keyword>
	<keyword>Registry</keyword>
</DOC>